Targeting autophagy in disease: established and new strategies

M Kocak, S Ezazi Erdi, G Jorba, I Maestro, J Farrés… - Autophagy, 2022 - Taylor & Francis
Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing
cytosolic aggregated proteins, damaged organelles or invading microorganisms …

Roles of mTOR complexes in the kidney: implications for renal disease and transplantation

D Fantus, NM Rogers, F Grahammer… - Nature Reviews …, 2016 - nature.com
The mTOR pathway has a central role in the regulation of cell metabolism, growth and
proliferation. Studies involving selective gene targeting of mTOR complexes (mTORC1 and …

mTOR pathway in colorectal cancer: an update

MG Francipane, E Lagasse - Oncotarget, 2013 - pmc.ncbi.nlm.nih.gov
The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug
development, particularly due to the fact that it plays such a crucial role in cancer biology. In …

Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury

J Agostinone, L Alarcon-Martinez, C Gamlin, WQ Yu… - Brain, 2018 - academic.oup.com
Dendrite pathology and synapse disassembly are critical features of chronic
neurodegenerative diseases. In spite of this, the capacity of injured neurons to regenerate …

Na+/K+-ATPase Revisited: On Its Mechanism of Action, Role in Cancer, and Activity Modulation

J Bejček, V Spiwok, E Kmoníčková, S Rimpelová - Molecules, 2021 - mdpi.com
Maintenance of Na+ and K+ gradients across the cell plasma membrane is an essential
process for mammalian cell survival. An enzyme responsible for this process, sodium …

Autophagy in kidney health and disease

Z Wang, ME Choi - Antioxidants & redox signaling, 2014 - liebertpub.com
Significance: Autophagy is emerging as an important pathway in many biological processes
and diseases. This review summarizes the current progress on the role of autophagy in …

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma

K Kuroshima, H Yoshino, S Okamura… - Cancer …, 2020 - Wiley Online Library
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial
growth factor, has been widely used as a first‐line treatment against metastatic renal cell …

The new antitumor drug ABTL0812 inhibits the Akt/mTORC1 axis by upregulating tribbles-3 pseudokinase

T Erazo, M Lorente, A López-Plana… - Clinical Cancer …, 2016 - AACR
Purpose: ABTL0812 is a novel first-in-class, small molecule which showed antiproliferative
effect on tumor cells in phenotypic assays. Here we describe the mechanism of action of this …

Mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives

S Faes, N Demartines, O Dormond - Frontiers in Cell and …, 2021 - frontiersin.org
Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in
the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently …

Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of …

J Dunn, S Ferluga, V Sharma, M Futschik, DA Hilton… - …, 2019 - thelancet.com
Background Meningioma is the most frequent primary intracranial tumour. Surgical resection
remains the main therapeutic option as pharmacological intervention is hampered by poor …